Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Stocks in this Quantisnow insightHealth Care
Historical context for JANX
Across the 7 sessions after earlier JANX headlines, the stock closed higher 4 times and lower 3 times, with a median move of 7.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JANX | SPY |
|---|---|---|---|
| Jan 26, 2026 | Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer | -1.1% | +0.5% |
| Jan 22, 2026 | Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors | +14.1% | +0.5% |
| Dec 24, 2025 | Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study | +1.3% | +0.4% |
| Dec 2, 2025 | Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC | -53.3% | +0.2% |
| Nov 24, 2025 | Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC | +9.5% | +1.5% |
| Nov 18, 2025 | Wolfe Research initiated coverage on Janux Therapeutics | +1.0% | -0.8% |
Quantisnow market dataNASDAQ
JANX
Janux Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for JANX
Full JANX profile on Quantisnow Follow JANX and get a push notification the moment its next story breaks.